BronchiEctasis Trial Testing ERdosteine (BETTER)

Phase 3

Recruiting

• Conditions: Bronchiectasis; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12621000315819
• Lead Sponsor: Queensland University of Technology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-03-22
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 194

Inclusion Criteria

1. Participants aged 2 to 49 years
2. Bronchiectasis with at least 2 acute respiratory exacerbations in the last 18 months AND
3. Able to be contacted for the 15 month follow up period.

Exclusion Criteria

1.Cystic fibrosis
2.Contraindication to erdosteine use (e.g. liver dysfunction, hypersensitivity, renal failure, deficiency of the cystathionine-synthetase enzyme, phenylketonuria, active peptic ulcer)
3.Pregnant, pregnancy planned (in next 12 months) or nursing mothers
4.Previously randomised
5.Hospitalised in the last 4 weeks for respiratory instability
6.Participation in another intervention concurrent RCT.

Study & Design

• Study Type: Interventional
• Study Design: Not specified